Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-690514 · 4 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| BMS-690514 | EXPERIMENTAL | - |
| BMS-690514 + Letrozole | ACTIVE_COMPARATOR | - |
| Lapatinib + Letrozole | ACTIVE_COMPARATOR | - |
| A1 | EXPERIMENTAL | - |
| B2 | ACTIVE_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-690514 | DRUG | Tablets, Oral, 200 mg, once daily, until disease progression or toxicity |
| Lapatinib | DRUG | Tablets, Oral, 1500 mg, once daily, \~ 12 months depending on response |
| Letrozole | DRUG | Tablets, Oral, 2.5 mg, once daily, \~ 12 months depending on response |
| Erlotinib | DRUG | Capsules, Oral, 150 mg, once daily, Until disease progression or toxicity |
Inclusion Criteria: * Recurrent, metastatic or progressive NSCLC without any indication of radiotherapy. Subjects must have: * Pathologically confirmed NSCLC * Previously received treatment with single agent Gefitinib or Erlotinib and completed treatment at least 2 weeks prior to study entry * Any ...
Top 20 of 92 competitors
BMS-690514 is an investigational small molecule being studied for the treatment of non-small-cell lung carcinoma, breast cancer, and other solid tumors. It is being developed by Bristol-Myers Squibb Company and has reached Phase 2 clinical development for these oncology indications.
BMS-690514 is a small molecule oncology drug. Its specific molecular target has not been disclosed in the available information, so its mechanism of action is not described here.
BMS-690514 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker BMY. The drug is an investigational small molecule in clinical development for oncology indications.
BMS-690514 is in Phase 2 clinical development for non-small-cell lung carcinoma, breast cancer, and other solid tumors. It is investigational and not yet approved by regulatory authorities. All completed clinical trials for the drug are Phase 1 studies.
BMS-690514 has been studied in several completed Phase 1 trials, including NCT00329004 in advanced solid tumors, NCT00420186 with paclitaxel and carboplatin, NCT00479583 with FOLFIRI and FOLFOX, and NCT00516451 in Japanese patients with solid tumors. These trials enrolled a total of 141 participants.
No alternative names for BMS-690514 have been reported. The drug is identified solely by its code name BMS-690514 in clinical trial records and development information.